GeoVax Labs Inc. Issues Letter To Shareholders

ATLANTA, GA--(Marketwired - April 06, 2015) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and Marburg viruses, and HIV using its novel platform technology, has provided shareholders with an annual update letter. The letter is distributed in GeoVax's 2014 Annual Report to Shareholders mailed on April 2, and can be read in full by visiting the following link: http://www.geovax.com/investors.html

In the letter, GeoVax President and CEO, Robert McNally, Ph.D, and Chairman, David Dodd, update shareholders on the Company's continued efforts to increase shareholder value through its key initiatives and developments, which include:

• Expansion of the Company's continued HIV development portfolio with the Ebola virus as the first target, which should provide a series of near-term achievable milestones, while its HIV program moves closer to a goal of an efficacy trial
  
  
• The development of a vaccine for each of the three major Ebola virus strains, plus Marburg, with the intention of allowing medical professionals the option to use an individual single-dose vaccine for an outbreak emergency, or all components together in a two-dose regimen for routine immunization
  
  
• Preventive HIV vaccine clinical trial initiatives and follow-on development expectations with the National Institutes of Health (HIV) and the HIV Vaccine Trials Network (HVTN)
  
  
• HIV Immunotherapy program update as it relates to the NIH's new push to find a cure for HIV through using a "shock and kill" strategy, in which patients remain on the standard-of-care, anti-retroviral drug therapy, while a second drug ("shock agent") to activate latent HIV and a third drug ("kill agent") to recognize and eliminate cells that harbor the latent HIV reservoir
  
  
• Update on the recent financing transaction of up to $6M to fund ongoing operations and move GeoVax's programs forward
  
  

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our novel vaccine platform. Our current development programs are focused on vaccines against Ebola and Marburg viruses, and Human Immunodeficiency Virus (HIV). We believe our technology and vaccine development expertise is well-suited for a wide variety of human infectious diseases for which there is an unmet medical need, and we intend to pursue expansion of our product pipeline as resources permit.

Our vaccine platform supports production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. Producing non-infectious virus-like particles in the person being vaccinated circumvents the need to purify virus-like particles for inoculation. The production of virus-like particles in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection should it appear.

Clinical trials for GeoVax's preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax's vaccines, in various doses and combinations, have been tested in close to 500 humans. For more information, go to www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent HIV or Ebola infection in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.